Other languages Astellas Pharma Inc.

Equities

4503

JP3942400007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-23 am EDT			5-day change	1st Jan Change
1,492 ^JPY	+1.05%		+3.15%	-11.54%

Apr. 22	Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	MT
Apr. 22	Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17
Middle East Tensions Blunt Asian Stock Markets Excepting China	Apr. 15
MIDDAY BRIEFING - Unternehmen und Märkte	Apr. 15
MÄRKTE ASIEN/Börsen stecken Eskalation im Nahen Osten gut weg	Apr. 15
Aktien Asien/Pazifik: Eskalation im Nahen Osten drückt die Kurse - CSI legt zu	Apr. 15
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	Apr. 15
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	Apr. 14
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	Mar. 28
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer	Mar. 26
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 22
Bayer plant Zulassungsantrag für neues Mittel gegen Wechseljahrsbeschwerden	Mar. 19
Bayer to seek approval for menopausal relief drug after third trial win	Mar. 19
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18
Hewlett Packard Enterprise's HPE Asset Upcycling Services Selected by Astellas Pharma	Mar. 14
Sandoz-Aktien nach Jahreszahlen mit Abgaben	Mar. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Astellas Pharma Inc.

Equities

4503

JP3942400007

Other languages

Filters